German Diagnostics: Life Gets Hard
In the past year, Germany, the largest health-care market in Europe and long considered a model of high-quality medical egalitarianism, has cut reimbursement for many in vitro diagnostics tests by 15-20%, mirroring trends in other European countries. In response, German laboratories are consolidating to reap the benefits of economies of scale, while their suppliers are paring expenses, reorganizing internally, and cutting prices.
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.